Malcolm K. Brenner
Member of the Scientific Advisory BoardDr. Malcolm K. Brenner, M.D. Ph.D. B.Chir. M.B. serves as Scientific Advisor for Vor Biopharma Inc. since February 2023. He serves as Co-Founder of March Biosciences Inc. and also serves as Member of Scientific Advisory Board since July 2025 and also served as Chair Scientific Advisory Board until July 2025. He was a Member of Scientific & Clinical Advisory Board at Valo Therapeutics Ltd from August, 2022 to April 2026. He is the Founding Director, Houston Methodist Hospital and Texas Children's Hospital. He served as Member of the Scientific Advisory Board at Triumvira Immunologics Inc since January 2022 until 2023. He serves as Member of the Scientific Advisory Board at Turnstone Biologics Corp. He serves as Member of Scientific Advisory Board of Turnstone Biologics Inc. He is a co-founder of ViraCyte, LLC. He is Member of Advisory Board at Abintus Bio, Inc. He is Member of the Scientific Advisory Board at Adaptimmune Therapeutics plc. Dr. Brenner has been Scientific Advisory Board Member of Allogene Therapeutics, Inc. since May 1, 2019. He serves as Member of Scientific Advisory Board at Memgen, LLC. Dr. Brenner has been Scientific Co-Founder & Scientific Advisor at Tessa Therapeutics Pte Ltd. He is a Professor of Medicine & Pediatrics and Founding Director of Center for Cell and Gene Therapy at Baylor College of Medicine. Dr. Brenner serves as an Editor-in-Chief of the journal Molecular Therapy. He served as a Scientific & Medical Advisor of MaxCyte, Inc. Dr. Brenner serves as Member of Advisory Board at TScan Therapeutics, Inc. He served as the President of the International Society of Hematotherapy and Graft Engineering and President-Elect of the American Society for Gene Therapy. From 1994 to 1997, he served as Director, Cell and Gene Therapy Program, St. Jude Children's Research Hospital. Dr. Brenner was Professor, Departments of Pediatrics and Medicine at the University of Tennessee and Director of Bone Marrow Transplant Division and Member of Department Hematology/Oncology at St. Jude Children's Research Hospital. He has been a Member of Scientific Advisory Board at Formula Pharmaceuticals, Inc. since May 5, 2016 and Marker Therapeutics, Inc. (formerly known as TapImmune, Inc.) since 2018. He serves as Member of Scientific Advisory Board of Torque Therapeutics Inc. He serves as a Member of Scientific Advisory Board of SillaJen Biotherapeutics, Inc. He is a co-founder of Allovir, Inc. and had been its Independent Non-Executive Director since 2012. Dr. Brenner served as Member of Scientific Advisory Board at Coya Therapeutics, Inc. He serves as a Member of Scientific Board at AGC Biologics S.p.A. (formerly known as MolMed S.p.A.) He serves as a Member of Medical and Scientific Advisory Board at CellExSys, Inc. In 1992, he was awarded the ALSAC Chair in Transplantation Research. He is also a member of the Texas Children’s Cancer and Hematology Center, the Stem Cell and Regenerative Medicine Center and the Dan L. Duncan Comprehensive Cancer Center at Baylor. Dr. Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT) and International Society for Cell and Gene Therapy. He served as a Member of Medical Advisory Board of Cellectis S.A. He has authored over 150 original research papers. Dr. Brenner is also member of the National Academy of Medicine. Dr. Brenner holds a Ph.D. from the University of Cambridge, where he became a fellow of the Royal College of Pathologists and the Royal College of Physicians; a M.B.Ch. B. from Westminster Medical College and a B.S. from the University of Cambridge. Dr. Brenner obtained his medical degrees from the University of Cambridge, England. He had been a Member of Scientific Advisory Board at bluebird bio, Inc. since March 2011 and Unum Therapeutics, Inc. since February 2, 2016.
Positions
- Company NameAdaptimmune Therapeutics plcStock CodeADAPYPositionMember of the Scientific Advisory BoardColleagues
- CJChristopher James HillCEO, CFO, Secretary & Director
- LMLawrence M. AllevaIndependent Non-Executive Chairman
- HKHelen Katrina Tayton-MartinCo-Founder
- JPJuli P. MillerVP of Corporate Affairs & Investor Relations
- DLDana LynchSenior Director of Corporate Communications
- KFKimberly FreemanVice President of Commercial Planning
- SAStephan A. GruppMember of the Scientific Advisory Board
- TGThomas GajewskiMember of the Scientific Advisory Board
- Company NameMarker Therapeutics, Inc.Stock CodeMRKRPositionMember of Scientific Advisory BoardColleagues
- JFJuan F. VeraCo-Founder, CEO, President, Treasurer, Secretary & Director
- NDNorman David EansorIndependent Chairman
- EDElizabeth DonnellyDirector of Administration
- MMMaria-Bernadette MadelDirector of Corporate Operations & External Communications
- ECEdmund CheungVice President of Human Resources
- PAPatricia AllisonHead of Clinical Operations
- KKKatharine KnobilIndependent Director
- MKMalcolm K. BrennerMember of Scientific Advisory Board
- HEHelen E. HeslopMember of Scientific Advisory Board
